Navigation Links
New Blood Thinner May Help Prevent Leg Clots, Study Finds
Date:12/10/2012

l of Medicine, to coincide with a planned presentation at the American Society of Hematology annual meeting in Atlanta.

Dr. Giancarlo Agnelli, director of the department of internal and cardiovascular medicine and stroke unit at Perugia University Hospital in Italy, and his colleagues randomly assigned almost 2,500 patients to one of three regimens for a year.

Patients were either given 2.5 milligrams (mg) of apixaban twice daily, 5 mg of apixaban twice daily or an inactive placebo. Over the course of the trial, the researchers looked for recurrent venous thromboembolism, deaths from venous thromboembolism or cardiovascular problems and major bleeding.

The investigators found that either dose of apixaban reduced the risk of recurrent venous thromboembolism and venous thromboembolism-related death by about 80 percent, compared with placebo.

While almost 9 percent of those receiving placebo had one of these events, only 1.7 percent of those taking apixaban did, the researchers reported.

In addition, either dose of apixaban reduced the risk of stroke, heart attack and cardiovascular-related death. Major bleeding was similar for those taking apixaban and those receiving placebo, the researchers noted.

"These results indicate that apixaban -- at both low and high doses -- provides an attractive risk-benefit profile for use as an ongoing treatment option in patients at risk of recurrent [venous thromboembolism]," Agnelli said in a statement.

"This regimen has the potential to eliminate many of the challenges we face when we treat patients with warfarin -- including drug and food interactions and the need for ongoing monitoring -- which can greatly simplify ongoing management of this condition," he added.

The trial was funded by the developers of apixaban, Bristol-Myers Squibb and Pfizer. Although the drug has not yet been approved by the U.S. Food and Drug Administration, a decision is expected in March, according to th
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. US Drug Watchdog Now Urges All DePuy ASR And DePuy Pinnacle Hip Implant Recipients To Get Blood Tests And To Call Them For The Names Of The Best Law Firms-Get Compensated
2. Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
3. Consider Weight When Choosing Blood Pressure Meds: Study
4. Honey Hollow Wagyu Announces New eCommerce Website to Bring Simplicity to Ordering 100% FullBlood Wagyu Beef Online
5. Studying marrow, URMC researchers accelerate blood stem cells
6. Unexpected toughness may mark out cancer cells in the blood
7. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Get A Blood Test For Elevated Levels Of Cobalt Or Chromium and to Call Them If The Levels Are high
8. New DNA-Based Blood Test May Spot Signs of Cancer
9. Johns Hopkins scientists pair blood test and gene sequencing to detect cancer
10. High Blood Pressure During Pregnancy Tied to Later Heart Trouble
11. Impaired blood vessel function found in cystic fibrosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Blood Thinner May Help Prevent Leg Clots, Study Finds
(Date:7/25/2014)... July 26, 2014 2014 ... Gel Permeation Chromatography Industry” is a professional ... and China Gel Permeation Chromatography market. The ... including Gel Permeation Chromatography definition, classification, application, ... industry overview. This research covers the international ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
(Date:7/25/2014)... are more easily distracted during thinking and memory tasks ... any type of memory test administered reveals a decline ... co-author Randi Martin, professor of psychology at Rice University, ... said, this study shows that "environmental interference" has a ... younger adults. The study included 60 seniors, aged ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
Breaking Medicine News(10 mins):Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Distractions Seem More Troublesome With Age 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2
... , , FREMONT, Calif., Nov. 24 ... today announced the launch of the VersaWave(R) Specialty Er:YAG all-issue dental ... Greater New York Dental Meeting, November 30 - December 3, 2008 ... , "The VersaWave Specialty builds on our solid heritage ...
... results yesterday evaluating the Novo-TTF device in vitro ... the device enhanced the efficacy of standard chemotherapy ... When used in combination with standard chemotherapy, the ... intensity alternating electric fields to destroy cancer cells, ...
... and Transportation System Reduces Endoscope Cross-contamination and Protects Scopes ... New Infection Prevention Solution for Busy GI Suites , ... 24 Advanced Sterilization Products (ASP), division of Ethicon ... CLEANASCOPE System, a new infection prevention solution designed to ...
... , , MONDAY, Nov. 24 (HealthDay News) -- The interaction between ... may contribute to epileptic seizures, new research suggests. , If ... be a target for new treatments or even preventive measures ... of Nature Medicine . , "This opens a window ...
... Recognized - , , WASHINGTON, Nov. ... definitive voice for 50+ Americans and the world,s largest-circulation magazine with ... Inspire Awards . The Inspire Awards pay tribute ... innovative thinking, passion and perseverance. The 2009 honorees include Glenn ...
... developer of,LifeShirt(R), a continuous, integrated and wearable remote ... proprietary LifeShirt(R),system is being used by Concordia ... factors that may put children at risk for ... Children enrolled in ...
Cached Medicine News:Health News:HOYA ConBio(TM) Introduces VersaWave(R) Specialty Laser 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:ASP Announces Availability of CLEANASCOPE System 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 3Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 4Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 5Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 6Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 7Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 8Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 2Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 3Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 4
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... BUENA, N.J. , July 24, 2014 ... New Jersey based specialty generic pharmaceutical company, ... resignation from its Board of Directors.  Mr. Finio has ... company, and under the terms of his acceptance of ... continue in his role as Director for IGI Laboratories, ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... at 9th International Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., ... a pivotal Phase II trial evaluating Revlimid in ... syndromes (MDS),were presented today by Dr. Alan List, ... Institute, at the 9th International,Symposium on MDS currently ...
Cached Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3